ATE506965T1 - Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation - Google Patents

Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation

Info

Publication number
ATE506965T1
ATE506965T1 AT02797854T AT02797854T ATE506965T1 AT E506965 T1 ATE506965 T1 AT E506965T1 AT 02797854 T AT02797854 T AT 02797854T AT 02797854 T AT02797854 T AT 02797854T AT E506965 T1 ATE506965 T1 AT E506965T1
Authority
AT
Austria
Prior art keywords
antibodies
mitotic
polypeptide antigens
cdc
cell
Prior art date
Application number
AT02797854T
Other languages
English (en)
Inventor
Arthur D Levinson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE506965T1 publication Critical patent/ATE506965T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT02797854T 2001-09-05 2002-09-04 Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation ATE506965T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05
PCT/US2002/028176 WO2003020909A2 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Publications (1)

Publication Number Publication Date
ATE506965T1 true ATE506965T1 (de) 2011-05-15

Family

ID=23233944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797854T ATE506965T1 (de) 2001-09-05 2002-09-04 Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation

Country Status (17)

Country Link
EP (1) EP1432446B1 (de)
JP (2) JP5224632B2 (de)
KR (3) KR20100061863A (de)
CN (2) CN101446590A (de)
AT (1) ATE506965T1 (de)
AU (1) AU2002332838B2 (de)
BR (1) BR0212641A (de)
CA (1) CA2457541C (de)
DE (1) DE60239881D1 (de)
DK (1) DK1432446T3 (de)
HU (1) HUP0500617A3 (de)
IL (2) IL160659A0 (de)
MX (1) MXPA04002084A (de)
NZ (1) NZ531515A (de)
PL (1) PL374363A1 (de)
WO (1) WO2003020909A2 (de)
ZA (1) ZA200401751B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
BRPI0410748B8 (pt) * 2003-05-20 2021-05-25 Immunogen Inc compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular
CN101087611B (zh) * 2003-10-10 2019-04-23 伊缪诺金公司 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物靶向特定细胞群的方法、所述偶联物和制备所述偶联物的方法
EP2247304B1 (de) * 2008-04-02 2016-05-25 MacroGenics, Inc. Her2/neu-spezifische antikörper und methoden zu ihrer verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
DE60020529T2 (de) * 1999-03-01 2006-04-27 Genentech Inc., San Francisco Antikörper zur krebsbehandlung und -diagnose
EP1226177B1 (de) * 1999-10-29 2008-07-09 Genentech, Inc. Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
WO2001055720A2 (en) * 2000-01-26 2001-08-02 Ventana Medical Systems, Inc. A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
EP1432446B1 (de) 2011-04-27
IL160659A0 (en) 2004-08-31
AU2002332838B2 (en) 2007-08-02
ZA200401751B (en) 2005-07-27
CN101446590A (zh) 2009-06-03
BR0212641A (pt) 2005-04-12
EP1432446A4 (de) 2004-09-08
EP1432446A2 (de) 2004-06-30
CA2457541A1 (en) 2003-03-13
DK1432446T3 (da) 2011-07-18
PL374363A1 (en) 2005-10-17
HUP0500617A2 (hu) 2005-10-28
MXPA04002084A (es) 2004-06-07
WO2003020909A3 (en) 2003-11-20
HUP0500617A3 (en) 2012-05-02
JP5224632B2 (ja) 2013-07-03
JP2010280691A (ja) 2010-12-16
JP2005517155A (ja) 2005-06-09
CN1578673A (zh) 2005-02-09
KR20040044850A (ko) 2004-05-31
KR20090104925A (ko) 2009-10-06
DE60239881D1 (de) 2011-06-09
NZ531515A (en) 2007-11-30
KR20100061863A (ko) 2010-06-09
WO2003020909A2 (en) 2003-03-13
IL160659A (en) 2011-07-31
CA2457541C (en) 2013-01-08

Similar Documents

Publication Publication Date Title
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
EP1463733A4 (de) Inhibitoren von mitotischem kinesin
ATE365562T1 (de) Zielgerichtete kombinations-immuntherapie für krebs
UA114879C2 (uk) Антитіло до cd38 для лікування раку
MXPA05006568A (es) Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
MXPA05002440A (es) Composiciones y kits para la eliminacion de compuestos irritantes de superficies corporales.
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004037235A3 (en) Method and composition for preventing and treating solid tumors
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
TW200640496A (en) Visco-supplement composition and methods
ATE506965T1 (de) Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation
IL158433A (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
WO2004060878A3 (en) Inhibitors of phosphatases
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
WO2002026730A3 (en) Fluorinated quinolones as antimitotic and antitumor agents
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties